Squarepoint
GANX icon

Squarepoint’s Gain Therapeutics GANX Stock Holding History

Squarepoint’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
+136,359
New +$251K ﹤0.01% 3871
2025
Q4 		– Sell
-38,537
Closed -$68.2K – 4477
2025
Q3 		$68.2K Buy
+38,537
New +$65K ﹤0.01% 4179

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Squarepoint's GANX Position: Q2 2026 in Review

Squarepoint opened a new position in Gain Therapeutics (GANX) in Q2 2026: 136,359 shares worth $277K. The stake represents ﹤0.01% of the portfolio and ranks #3871 among its holdings. This is a return to the name: Squarepoint previously reported a position in GANX as recently as Q3 2025.

Squarepoint first reported a position in GANX in Q3 2025 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Squarepoint held 136,359 shares of Gain Therapeutics worth $277K as of Q2 2026.
  • Gain Therapeutics was a new Squarepoint position in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3871 holding.
  • Squarepoint first reported a position in Gain Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.